In Ando et al., 2017, numerical errors in the axonal rate were published in Results and Discussion sections and Fig. 1. The corrected values are shown below.
The axonal rate should have been 62/801 instead of 63/801.
Results (page 193)
We analyzed 1,334 unrelated patients with clinically suspected CMT. We detected 30 known pathogenic mutations, 1 novel pathogenic mutation, 14 novel likely pathogenic variants of MFN2, from which 44 were heterozygous mutations and 1 was compound heterozygous mutation. Of the CMT patients without PMP22 duplication/deletion, 801 patients (60%) presented the axonal phenotype, and 367 patients (28%) were classified as having the demyelinating type. We could not classify 166 patients due to a non‐recordable median compound motor action potential (CMAP) or no electrophysiological data. These CMT patients with axonal phenotype showed an MFN2 mutation rate of 8%, 62/801 (Fig. 1A).
Figure 1.
Study flow chart of this and onset age distribution. (A) Study flow chart and the rate of MFN2 mutations in axonal Charcot‐Marie‐Tooth disease (CMT). Onset age distribution for the axonal type and cases with MFN2 mutation.
Discussion (page 197)
In this Japanese case series, we detected MFN2 mutations in 79 of 1,334 CMT patients without a PMP22 deletion/duplication. The MFN2 mutation accounted for 16% of the CMT2 patients in a Spanish cohort study, and 18% of CMT2 without MPZ and GJB1 mutations in French patients (Calvo et al., 2009 ; Casasnovas et al., 2010 ). In Asia, MFN2 was the cause of CMT2 in 23% of Korean CMT2 patients and 18% of Chinese CMT2 patients (Choi et al., 2015 ; Xie et al., 2016 ). The frequency of MFN2 mutations is low, between 9% and 11%, as previously reported in a Japanese population study (Kijima et al., 2005 ; Abe et al., 2011 ). Here, we show a frequency of the MFN2 mutation of 8% (62/801) in Japanese CMT2 patients. A frequency of 28%–34% for sporadic or de novo mutations has been previously reported (Verhoeven et al., 2006 ; Choi et al., 2015 ). However, sporadic cases reached a frequency of 46% in our study. This incidence rate is higher than that reported from other countries. The low frequency of MFN2 mutations and high frequency of sporadic cases might indicate the influence of geographical and social distribution, although there is a possibility of an incomplete family history.
Figure. 1 (page 193)
The pie chart of diagnostic rate in axonal CMT should have been 7.7 instead of 7.9 in MFN2 rate and 20.5 instead of 8.7 in Other genes.
We apologize for these errors.
References
- Abe A, Numakura C, Kijima K, Hayashi M, Hashimoto T, Hayasaka K (2011). Molecular diagnosis and clinical onset of Charcot‐Marie‐Tooth disease in Japan. J Hum Genet 56:364–368. [DOI] [PubMed] [Google Scholar]
- Ando M, Hashiguchi A, Okamoto Y, Yoshimura A, Hiramatsu Y, Yuan J, Higuchi Y, Mitsui J, Ishiura H, Umemura A, Maruyama K, Matsushige T, Morishita S, Nakagawa M, Tsuji S, Takashima H (2017). Clinical and genetic diversities of Charcot‐Marie‐Tooth disease with MFN2 mutations in a large case study. J Peripher Nerv Syst 22:191–199. 10.1111/jns.12228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Calvo J, Funalot B, Ouvrier RA, Lazaro L, Toutain A, De Mas P, Bouche P, Gilbert‐Dussardier B, Arne‐Bes MC, Carriere JP, Journel H, Minot‐Myhie MC, Guillou C, Ghorab K, Magy L, Sturtz F, Vallat JM, Magdelaine C (2009). Genotype‐phenotype correlations in Charcot‐Marie‐Tooth disease type 2 caused by mitofusin 2 mutations. Arch Neurol 66:1511–1516. [DOI] [PubMed] [Google Scholar]
- Casasnovas C, Banchs I, Cassereau J, Gueguen N, Chevrollier A, Martinez‐Matos JA, Bonneau D, Volpini V (2010). Phenotypic spectrum of MFN2 mutations in the Spanish population. J Med Genet 47:249–256. [DOI] [PubMed] [Google Scholar]
- Choi BO, Nakhro K, Park HJ, Hyun YS, Lee JH, Kanwal S, Jung SC, Chung KW (2015). A cohort study of MFN2 mutations and phenotypic spectrums in Charcot‐Marie‐Tooth disease 2A patients. Clin Genet 87:594–598. [DOI] [PubMed] [Google Scholar]
- Kijima K, Numakura C, Izumino H, Umetsu K, Nezu A, Shiiki T, Ogawa M, Ishizaki Y, Kitamura T, Shozawa Y, Hayasaka K (2005). Mitochondrial GTPase mitofusin 2 mutation in Charcot‐Marie‐Tooth neuropathy type 2A. Hum Genet 116:23–27. [DOI] [PubMed] [Google Scholar]
- Verhoeven K, Claeys KG, Zuchner S, Schroder JM, Weis J, Ceuterick C, Jordanova A, Nelis E, De Vriendt E, Van Hul M, Seeman P, Mazanec R, Saifi GM, Szigeti K, Mancias P, Butler IJ, Kochanski A, Ryniewicz B, De Bleecker J, Van den Bergh P, Verellen C, Van Coster R, Goemans N, Auer‐Grumbach M, Robberecht W, Milic Rasic V, Nevo Y, Tournev I, Guergueltcheva V, Roelens F, Vieregge P, Vinci P, Moreno MT, Christen HJ, Shy ME, Lupski JR, Vance JM, De Jonghe P, Timmerman V (2006). MFN2 mutation distribution and genotype/phenotype correlation in Charcot‐Marie‐Tooth type 2. Brain 129:2093–2102. [DOI] [PubMed] [Google Scholar]
- Xie Y, Li X, Liu L, Hu Z, Huang S, Zhan Y, Zi X, Xia K, Tang B, Zhang R (2016). MFN2‐related genetic and clinical features in a cohort of Chinese CMT2 patients. J Peripher Nerv Syst 21:38–44. [DOI] [PubMed] [Google Scholar]